The cleaning and household products giant behind some of the most durable consumer brands in America just had its CEO announce a health-related transition, is carrying an ERP headwind that should lap in FY2027, yields over 5%, and reports Q4 on August 3 against a bar that has been lowered repeatedly.
Get the breakdown of whether the Dividend King income case and the recovery setup justify buying into the uncertainty now.
Post-IPO AI Play (Sponsored)
SpaceX just completed one of the biggest IPOs in market history.
But Louis Navellier says the next major opportunity may not be SpaceX at all.
A new federal AI initiative could shift billions toward a different kind of technology — and one little-known AI company may be positioned before most investors catch on.
He is revealing the full setup, including the company name, in a free briefing.
Watch the free AI briefing here.
*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
Q4 Reports August 3, and the Bar Has Been Cut to the Floor
The Clorox Company (NYSE: CLX) closed at $98.71. Q4 fiscal 2026 results are confirmed for August 3, 2026. The Q4 consensus EPS estimate is $1.66, against $2.87 a year ago.
That comparison looks brutal because fiscal 2026 has been dominated by an ERP migration that hit shipments and reported earnings, not because consumers stopped buying cleaning products.
The full-year FY2026 EPS consensus is $5.53, down from $5.80 ninety days ago. The stock's earnings growth estimate for fiscal 2026 is negative 28%, while the S&P 500 is growing earnings at roughly 24%. That gap explains the price.
The reason to pay attention is what comes next. FY2027 consensus EPS is $6.08, which is 10% growth above this year's depressed base.
The accounting drag ends, and the recovery begins. At $98.71 and $6.08 in FY2027 earnings, you are buying at roughly 16x the recovery year, not the hard year.
Q4 consensus EPS $1.66 vs year-ago $2.87: Ugly comparison driven by accounting, not consumer demand.
Full-year FY2026 consensus EPS $5.53, down from $5.80 ninety days ago: Estimates have been drifting lower all year.
FY2027 consensus EPS $6.08, roughly 10% above this year: The recovery is already in the analyst models.
At $98.71, roughly 16x FY2027 consensus earnings: Paying for the recovery year, not the hard year.
Q3 FY2026 showed what happens when the business clears a low bar: EPS of $1.64 against a $1.54 estimate, a clean 6% beat. The business can still surprise when expectations are realistic.
Action: Buy CLX at $97 to $100. At roughly 16x FY2027 consensus earnings with a 5% yield, you are paying for a business in the middle of a known, temporary accounting disruption, not a structurally broken one.
Exit if the quarterly dividend is cut.
Self-Driving AI (Sponsored)
Marc Chaikin’s system once flashed bearish on a little-known auto tech stock before it fell 35%.
Now that same system has flipped to “Very Bullish” after the company landed a major Nvidia-linked partnership tied to the future of self-driving cars.
Chaikin says this could be a better way to play the autonomous vehicle boom than Tesla.
See the ticker Chaikin is watching now
The CEO Is Transitioning and That Changes the Risk Calculus
In June 2026, Chair and CEO Linda Rendle announced a planned transition due to health reasons. A successor search is underway, and the current team stays in place until one is named.
Alongside the transition, Clorox restructured its operating model in June, appointed a new COO, and streamlined leadership oversight. The language from the board has been orderly and planned.
This matters because the FY2027 recovery requires sustained execution across several consecutive quarters. The ERP normalization, the IGNITE cost savings program, and the new business integrations all need management continuity to deliver on time.
A messy CEO transition introduces timing risk to when those benefits actually land. A clean one preserves the recovery schedule.
CEO Linda Rendle announced a health-related transition in June 2026: Planned, orderly, not a sudden departure.
New COO appointed and operating structure streamlined simultaneously: Leadership is being reinforced, not hollowed out.
Successor search underway, current team remains in place: No operational gap during the transition.
Right now, the board's actions support a smooth handoff. Watch whether that changes.
Action: On the August 3 call, listen for any update on the CEO successor timeline. A named replacement removes the leadership overhang immediately and is a signal to add.
No update means hold current position size and wait.
NYC Signals More (Sponsored)
Last year I ran for Mayor of New York City... and lost to a 34-year-old Democratic Socialist.
Now he wants to spend $70 million just to study government-run grocery stores.
Raise property taxes 9.5%.
And hike taxes on every corporation and high earner.
I've spent 30 years on Wall Street.
And I'm convinced what's starting in New York is just the beginning.
I've put together a free analysis explaining exactly what's coming, and what you can do about it.
Read it here.
FY2026 Is Painful Because of Accounting. FY2027 Is Where the Math Gets Interesting
The two-year ERP migration created an inventory timing reversal that has been dragging on reported sales and earnings throughout fiscal 2026.
Management confirmed this is temporary and tied specifically to how the ERP handled inventory recognition during the transition, not to any underlying weakness in how consumers are buying cleaning products, trash bags, or charcoal.
In FY2027, that reversal laps.
Management has named three specific tailwinds expected to materialize in the recovery year: the ERP lapping benefit itself, normalization of incentive compensation that was elevated during the transition, and the GOJO integration, which is expected to add significant revenue to the top line.
Cost savings from the IGNITE productivity program that were delayed due to ERP complexity are also expected to strengthen into FY2027.
ERP reversal laps in FY2027: The accounting drag ends on a schedule analysts can track.
IGNITE cost savings expected to strengthen in FY2027: A productivity benefit still coming, not behind.
Three named FY2027 tailwinds from management: ERP lap, incentive comp normalization, GOJO integration.
FY2027 consensus EPS $6.08 is already building in the recovery: Analysts are already modeling it.
The recovery thesis does not require anything unusual. The accounting headwind stops, the cost program lands, and the consumer stays stable. None of those need to be exceptional.
Action: On the August 3 call, listen for the first official FY2027 guidance. Any language confirming the ERP lap is on schedule is the confirmation signal. Hold through it.
A 5% Yield on 47 Years of Consecutive Increases Is the Income Case
Clorox has raised its dividend every year for 47 consecutive years. The annual payout is $4.96 per share. At $98.71, that yields just over 5%. For context, this is one of the highest yields this stock has offered in roughly a decade, entirely because the stock has fallen while the dividend has continued to rise.
The 47-year streak has survived the 2008 financial crisis, the 2020 pandemic, the 2023 cyberattack that disrupted Clorox's operations for months, and now the current ERP transition. The dividend grew through every single one of those.
That does not happen at companies where cash generation is fragile. It happens at companies where consumers keep buying the same products regardless of what the macro environment is doing. People buy disinfectant wipes in recessions.
They buy Kingsford charcoal every summer without thinking once about yield curves.
47 consecutive annual dividend increases: Survived 2008, COVID, a cyberattack, and now an ERP migration.
Annual payout $4.96, yield just over 5%: Among the highest yields this stock has offered in a decade.
Dividend covered by free cash flow through the disruption: The accounting noise does not touch the cash.
At 5%, you are paid to wait for FY2027. That is a different investment logic than buying a growth stock and hoping a catalyst arrives on schedule.
Action: If CLX pulls back toward $93 to $95 before August 3, the yield moves above 5.2%. Treat pre-earnings weakness as a better entry, not a reason to step back.
The Brands Still Hold Their Shelf Positions Despite the Operational Chaos
Clorox wipes. Glad trash bags. Kingsford charcoal. Hidden Valley Ranch. Burt's Bees. Brita. These are category defaults that consumers reach for without much deliberation.
That behavioral stickiness is what has protected Clorox from private label competition in its core categories through cycles when you would expect switching.
The recent operating data confirms it. International and professional segments have been consistently gaining share. Glad has turned positive. Cleaning has maintained its position even while shipments were disrupted by the ERP migration.
The business that the accounting has been obscuring is not as damaged as the earnings trajectory implies.
FY2027 revenue consensus sits at $7.57 billion against $6.66 billion this year, implying roughly 14% growth. That is not a business the market expects to keep shrinking.
International and professional segments are consistently gaining share: Growth running independent of the domestic ERP disruption.
Glad turned positive, cleaning maintaining position: The brand health is intact where you need it most.
FY2027 revenue consensus $7.57B vs $6.66B this year: The revenue recovery is already in the models.
The disruption hurt shipments and accounting. It did not hurt consumer preference or shelf position.
Action: On the August 3 call, watch category share data for wipes and bags. If market share is holding or gaining despite the operational disruption, the brand thesis is intact.
Poll: Deep value vs. quality at a fair price — which style do you prefer?
The Risks Are Specific, and Two of Them Are Active Right Now
Analyst sentiment is not bullish. Goldman Sachs carries a Sell with a target in the low $80s. JPMorgan is Underweight. Morgan Stanley is Equal Weight around $97. Only Jefferies has a Buy above the current price.
When the analyst community is predominantly at Hold or lower on a consumer staples Dividend King, either the business is structurally broken or the estimates have not yet fully reflected the recovery.
The FY2027 consensus of $6.08 suggests analysts do expect improvement, but they are not confident in the near-term path.
Q4 itself is expected to show revenue of $1.91 billion against $1.99 billion a year ago, a roughly 4% decline. The earnings comparison is down sharply year over year.
If Q4 misses the $1.66 EPS consensus or management guides FY2027 below what analysts already expect, the stock goes lower before the recovery narrative can take hold.
The CEO transition is the execution risk that ties all of it together. The recovery requires several consecutive quarters of solid execution. A prolonged or complicated leadership search introduces timing risk precisely when the business needs consistency.
Q4 revenue estimate $1.91B vs $1.99B a year ago: Revenue decline already expected. The bar is set for bad news.
Goldman Sachs Sell, JPMorgan Underweight, Morgan Stanley Equal Weight: The analyst community is not cheering this one.
CEO transition adds execution risk to a multi-quarter recovery: The hardest quarters are the ones ahead.
Action: Hard stop at $88. If CLX breaks below $88 on a Q4 print where EPS misses and FY2027 guidance comes in below the $6.08 consensus, the recovery timeline has extended materially. Exit at $88.
Final Word: A Dividend King at Its Highest Yield in Years, With Headwinds That Lap on Schedule
47 consecutive dividend increases. Over 5% yield. Q4 on August 3. FY2027 recovery in analyst models at $6.08. CEO transition underway. Analyst consensus mostly cautious.
Buy this for the income and the FY2027 recovery, not a quick re-rate. At 16x the recovery year earnings with a 5% yield, the math makes sense for patient investors.
Buy CLX at $97 to $100. Hard stop $88. Target $115 to $120 as FY2027 earnings normalize.
Setup Scorecard
Entry Window: $97 to $100. Yield over 5%, roughly 16x FY2027 consensus earnings of $6.08.
Catalyst Watch: Q4 results August 3, FY2027 initial guidance on that call, CEO successor announcement, Q4 EPS vs $1.66 consensus.
Upside Setup: ERP lap confirms in FY2027, IGNITE savings land, CEO succession orderly. Stock moves from 16x FY2027 earnings toward 19x as execution confirms recovery. Target $115 to $120 over 12 to 18 months.
Downside Cushion: 5% yield on 47-year dividend streak, brand category dominance in wipes, bags, and charcoal, FY2027 consensus already building in 10% earnings recovery, free cash flow covering the dividend through the disruption.
What Moves It Next: August 3 Q4 EPS vs $1.66, FY2027 guidance vs $6.08 consensus, CEO succession announcement, category share data for wipes and bags.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
